JP2018048151A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018048151A5 JP2018048151A5 JP2017192907A JP2017192907A JP2018048151A5 JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5 JP 2017192907 A JP2017192907 A JP 2017192907A JP 2017192907 A JP2017192907 A JP 2017192907A JP 2018048151 A5 JP2018048151 A5 JP 2018048151A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cancer stem
- brain tumor
- pharmaceutical composition
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000004663 cell proliferation Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 102000050554 Eph Family Receptors Human genes 0.000 claims 1
- 108091008815 Eph receptors Proteins 0.000 claims 1
- 102000051096 EphA2 Receptor Human genes 0.000 claims 1
- 108010055196 EphA2 Receptor Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 108060002566 ephrin Proteins 0.000 claims 1
- 102000012803 ephrin Human genes 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10185930.4 | 2010-10-01 | ||
| EP10185930A EP2446895A1 (en) | 2010-10-01 | 2010-10-01 | EPH receptor expression in tumor stem cells |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015200808A Division JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Division JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018048151A JP2018048151A (ja) | 2018-03-29 |
| JP2018048151A5 true JP2018048151A5 (enExample) | 2018-05-17 |
| JP6618968B2 JP6618968B2 (ja) | 2019-12-11 |
Family
ID=43856109
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2017192907A Active JP6618968B2 (ja) | 2010-10-01 | 2017-10-02 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530753A Pending JP2013540117A (ja) | 2010-10-01 | 2011-09-30 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
| JP2015200808A Active JP6523910B2 (ja) | 2010-10-01 | 2015-10-09 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019205190A Pending JP2020037579A (ja) | 2010-10-01 | 2019-11-13 | 腫瘍幹細胞におけるｅｐｈ受容体発現 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9078857B2 (enExample) |
| EP (2) | EP2446895A1 (enExample) |
| JP (4) | JP2013540117A (enExample) |
| KR (2) | KR101719966B1 (enExample) |
| AU (1) | AU2011310109B2 (enExample) |
| CA (1) | CA2813101C (enExample) |
| DK (1) | DK2621513T3 (enExample) |
| ES (1) | ES2616444T3 (enExample) |
| NZ (1) | NZ609594A (enExample) |
| PL (1) | PL2621513T3 (enExample) |
| WO (1) | WO2012042021A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2592672C9 (ru) | 2010-12-08 | 2016-11-27 | СтемСентРкс, Инк. | Новые модуляторы и способы их применения |
| SA112330278B1 (ar) | 2011-02-18 | 2015-10-09 | ستيم سينتركس، انك. | مواد ضابطة جديدة وطرق للاستخدام |
| EP2733206A1 (en) * | 2012-11-19 | 2014-05-21 | Naroa LLC | Method for the isolation for mammalian stem cells using EphA2 and uses thereof |
| EP3065780A1 (en) | 2013-11-04 | 2016-09-14 | Pfizer Inc. | Anti-efna4 antibody-drug conjugates |
| DK3137114T3 (da) | 2014-04-30 | 2021-01-25 | Pfizer | Anti-PTK7-antistof-lægemiddelkonjugater |
| CA2970140A1 (en) | 2014-12-10 | 2016-06-16 | Hyperstem, SA | Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brain tumors |
| CA2985345A1 (en) | 2015-05-08 | 2016-11-17 | FlowJo, LLC | Data discovery nodes |
| IL289849B2 (en) | 2015-11-10 | 2024-01-01 | Nat Inst Biotechnology Negev Ltd | Means and methods for reducing tumorigenicity of cancer stem cells |
| JP7680047B2 (ja) * | 2020-03-31 | 2025-05-20 | 慶應義塾 | ゲノム編集多能性幹細胞を用いた治療薬 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682173A4 (en) * | 2003-10-15 | 2007-10-31 | Medimmune Inc | EPHA2 VACCINE ON LISTERIA BASE |
| CA2577329A1 (en) * | 2004-08-16 | 2006-03-02 | Medimmune, Inc. | Eph receptor fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity |
| US20070248628A1 (en) * | 2005-12-06 | 2007-10-25 | Keller Lorraine H | Immunogens in cancer stem cells |
| US8343461B2 (en) * | 2006-03-08 | 2013-01-01 | Wake Forest University Health Sciences | Molecular signature of cancer |
| KR101521668B1 (ko) * | 2007-08-30 | 2015-05-28 | 다이이찌 산쿄 가부시키가이샤 | 항ｅｐｈａ２ 항체 |
-
2010
- 2010-10-01 EP EP10185930A patent/EP2446895A1/en not_active Withdrawn
-
2011
- 2011-04-18 US US13/089,217 patent/US9078857B2/en active Active
- 2011-09-30 JP JP2013530753A patent/JP2013540117A/ja active Pending
- 2011-09-30 CA CA2813101A patent/CA2813101C/en active Active
- 2011-09-30 PL PL11778540T patent/PL2621513T3/pl unknown
- 2011-09-30 WO PCT/EP2011/067114 patent/WO2012042021A1/en not_active Ceased
- 2011-09-30 KR KR1020167002577A patent/KR101719966B1/ko active Active
- 2011-09-30 EP EP11778540.2A patent/EP2621513B1/en active Active
- 2011-09-30 ES ES11778540.2T patent/ES2616444T3/es active Active
- 2011-09-30 DK DK11778540.2T patent/DK2621513T3/en active
- 2011-09-30 AU AU2011310109A patent/AU2011310109B2/en active Active
- 2011-09-30 NZ NZ609594A patent/NZ609594A/en unknown
- 2011-09-30 KR KR1020137011310A patent/KR20130095286A/ko not_active Ceased
-
2015
- 2015-10-09 JP JP2015200808A patent/JP6523910B2/ja active Active
-
2017
- 2017-10-02 JP JP2017192907A patent/JP6618968B2/ja active Active
-
2019
- 2019-11-13 JP JP2019205190A patent/JP2020037579A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018048151A5 (enExample) | ||
| JP5902138B2 (ja) | 癌治療と幹細胞調節のための方法 | |
| MX2024010140A (es) | Nuevos metodos. | |
| MY199967A (en) | Combinations of lsd1 inhibitors for use in the treatment of solid tumors | |
| AR060150A1 (es) | Heteropentaciclos activos como inhibidores de quinasas, y su uso para tratar trastornos de la proliferacion celular | |
| JP2015520753A5 (enExample) | ||
| JP2019516754A5 (enExample) | ||
| RU2018109902A (ru) | Виды комбинированной терапии для лечения рака | |
| MX2021002322A (es) | Nuevos metodos. | |
| JP2016501013A5 (enExample) | ||
| JP2007526248A5 (enExample) | ||
| MX354210B (es) | Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas. | |
| WO2007055941A3 (en) | Histone deacetylase inhibitors with aryl-pyrazolyl motifs | |
| WO2016145234A3 (en) | Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same | |
| MX2011010425A (es) | Agentes terapeuticos para el tratamiento de enfermedades asociadas con una proliferacion celular indeseada. | |
| JP2015514778A5 (enExample) | ||
| Ding et al. | Overexpression of miR-582-5p inhibits the apoptosis of neuronal cells after cerebral ischemic stroke through regulating PAR-1/Rho/Rho axis | |
| RU2015140572A (ru) | Способы лечения колоректального рака | |
| JP2013511560A5 (enExample) | ||
| WO2018175323A4 (en) | Gemcitabine derivatives for cancer therapy | |
| JP2013507954A5 (enExample) | ||
| Wang et al. | Gene therapy for vein graft failure | |
| JP2017516832A5 (enExample) | ||
| WO2005028617A3 (en) | Antisense inhibition of laminin-8 expression to inhibit human gliomas | |
| Maik-Rachline et al. | RAF, MEK and ERK inhibitors as anti-cancer drugs: Intrinsic and acquired resistance as a major therapeutic challenge |